At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of ductal carcinoma in situ (DCIS) within the past 6 months
- ✓DCIS locally excised with tumor-free margins of at least 1 mm
- ✓Estrogen or progesterone receptor positive with ≥5% positive cells
- ✓Age 40 to 70 years old
- ✕Prior deep vein thrombosis (DVT)
- ✕Prior transient ischemic attack (TIA)
- ✕Prior cerebrovascular accident (stroke)
- ✕Prior pulmonary embolism
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
International Breast Cancer Intervention Study II (IBIS-II) (DCIS)
In Brief
A Phase 3 clinical trial evaluating tamoxifen citrate and Anastrozole for Breast Cancer. Completed, enrolled 2,980 participants across 97 sites in 14 countries.
Detailed Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen. It is not yet known whether tamoxifen is more effective than anastrozole in preventing breast cancer after surgery for ductal carcinoma in situ. PURPOSE: This randomized phase III trial is studying how well adjuvant tamoxifen works compared to anastrozole in treating postmenopausal women who have undergone surgery to remove ductal carcinoma in situ.
Study Details
Timeline
Interventions
Tamoxifen 20mg + Anastrozole placebo
Anastrozole 1mg + Tamoxifen placebo